Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07242417 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

StatusRecruiting
PhaseEarly Phase 1
Started2025-12-18
View on ClinicalTrials.gov ↗

Amendment history

2026-01-19
Not Yet Recruiting→Recruiting Study Status, Oversight, Conditions, Outcome Measures, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-11-18→confirmed 2025-12-18
Study sites1→2
Secondary endpoints1 entry, revised
TheTumor EfficacyResponse ofand TC-G203Survival Outcomes
Primary endpoints2 to 1 entries
The SafetyIncidence of TCDose-G203 TheLimiting SafetyToxicities of(DLT) TC-G203and Maximum Tolerated Dose (MTD)
2025-11-17
Original filing
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Trial Details
NCT Number NCT07242417
Lead Sponsor Beijing GoBroad Hospital
Conditions Solid Cancer, GPC3 Positive Hepatocellular Carcinoma
Enrollment 30 participants
Start Date 2025-12-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-21